Scientists from Trinity College Dublin have developed what they describe as a promising gene therapy to treat glaucoma. The team previously showed ‘AAV-eNdi1’ offered promise in treating dry age-relat
A novel silk-derived protein could be a potential treatment for dry eye disease (DED), according to US authors of a study published in American Journal of Ophthalmology. Conducted across 26 sites
ATSN-101, a gene therapy for patients with Leber congenital amaurosis (LCA) caused by biallelic mutations in GUCY2D, produced an average 100-fold vision improvement among 15 trial participants, with t
EssilorLuxottica has completed acquisition of an 80% stake in Heidelberg Engineering. The agreement represents a step forward in EssilorLuxottica’s strategy and its med-tech journey, said the compa
Over a year post surgery, the US researchers who performed the world’s first whole-eye transplant concluded it’s a feasible procedure, citing evidence of preservation of retinal viability and perfusio
Wellington optometrist Ravi Dass, founder of the Foureyes Foundation, is seeking optical partnerships to sustain a long-term expansion of vision services for primary-school-aged kids in Aotearoa.
Berlin-based startup Even Realities has released its first Rx-able smartglasses, the G1.
Drs Verona Botha and Ammar Binsadiq have joined Associate Professor James McKelvie at his Waikato-based clinic Eye Surgeons, to accommodate growing demand from population growth and shifting demographics.
What is expected to be permanent Pharmac funding of Ilevro, a non-steroidal anti-inflammatory drop for post-cataract surgery patients, has been welcomed by New Zealand eyecare professionals.
Rayner, a global manufacturer of cataract surgery products, has launched a world-first spiral intraocular lens (IOL) designed using artificial intelligence (AI): RayOne Galaxy and Galaxy Toric.
Following data revealing patient complaints jump significantly with increasing age of their doctor, the Medical Board of Australia (MBA) is considering regular health checks for medical practitioners over 70 years old.
One-year study results from the phase 3 Essence-2 open-label extension (OLE) study for cyclosporine ophthalmic solution 0.1% (Vevye) have shown sustained safety and efficacy in treating the signs and symptoms of dry eye disease (DED).